RASA1 and neoplasm: Importantly, to exclude the possibility that this observation was influenced by patient specific effects, we performed a similar experiment in which we targeted upstream exons or the GAP domains of NF1 and RASA1 in engineered tumor organoids that are also deficient in APC and TP53 (commonly referred to as tumor progression organoid 2 (TPO2)) [55].